510(k) Clearance Without the Complexity — Expert FDA 510(k) Submission Services
FDA 510(k) submission is the gateway to the world’s largest medical device market. RABT Global’s specialist 510(k) consulting team gives your Class II device the strategic edge — from predicate selection to clearance.
Free 30-minute call with our FDA submission specialists. We’ll review your device and outline your 510(k) strategy.
A 510(k) (Pre-Market Notification) is the FDA’s primary approval pathway for Class II medical devices entering the US market. It requires you to demonstrate that your device is ‘substantially equivalent’ to a legally marketed predicate device — in intended use, technology, and safety/performance.
Who needs a 510(k)?
Any manufacturer of a Class II medical device (or certain Class I devices with special controls) intending to sell in the United States — whether manufactured in the US or internationally.
510(k) is NOT required for…
Class I devices (most are exempt) | Class III devices (need PMA) | Truly novel devices with no predicate (consider De Novo) | Devices already subject to a 510(k) exemption
RABT Global’s 6-Step 510(k) Submission Journey
Regulatory Strategy (Week 1–2)
Confirm device classification, identify best predicate,
determine appropriate 510(k) type (Traditional / Abbreviated / Special),
and map data requirements.
Pre-Submission Meeting (Q-Sub) (Week 3–6)
Prepare and submit a Q-Submission to the FDA to seek agreement
on your predicate strategy, testing requirements, and proposed
SE claims before full submission.
Performance Testing Planning (Week 4–8)
Identify all required bench, electrical safety,
biocompatibility, sterility, and software testing.
Review protocols before testing begins to avoid costly repeats.
Technical Dossier Preparation (Week 6–14)
Compile the full 510(k) dossier — device description,
predicate comparison, risk analysis, performance testing summaries,
labeling, and all required sections.
eSTAR Publishing & FDA Submission (Week 14–15)
Publish your dossier in FDA’s eSTAR format, conduct
pre-submission technical validation, and submit via FDA’s
ESG electronic gateway.
FDA Review & Response Management (Week 16 onwards)
Track your submission through FDA Acceptance Review and
Substantive Review. Respond to any Additional Information (AI)
requests within FDA timelines to protect your review clock.
510(k) vs De Novo vs PMA — Which Pathway is Right for Your Device?
| Factor | 510(k) | De Novo | PMA |
|---|---|---|---|
| Device Class | Class II | Novel Class II (no predicate) | Class III |
| Predicate Required? | Yes — substantial equivalence | No — risk-based framework | No — safety/effectiveness data |
| FDA Review Time | ~90 days (Standard) | ~12 months | ~180+ days |
| Clinical Data Required? | Often not required | Sometimes required | Yes — pivotal study required |
| Market Impact | Large Class II market | Creates new device type classification | High-risk, high-value devices |
| RABT Recommendation | Best option if a valid predicate exists | Consider if your device is genuinely novel | Required for life-sustaining/implantable Class III |
| RABT Support Available? | Yes — full 510(k) service | Yes — De Novo advisory | Yes — PMA strategy & support |
Our FDA 510(k) Submission Services — Full Scope
Regulatory Pathway Determination
confirm whether 510(k), De Novo, or PMA is the right route for your device
Device Classification Review
confirm your device’s FDA classification (class, product code, regulation number)
Predicate Device Strategy
systematic predicate identification and substantial equivalence argumentation
Q-Submission (Pre-Sub) Management
prepare and manage pre-submission meeting requests to align FDA on your strategy before full submission
510(k) Technical Documentation
full dossier preparation including device description, substantial equivalence report, performance testing summary, labeling
eSTAR Publishing & Submission
prepare and submit your 510(k) in FDA’s required eSTAR electronic format
FDA Deficiency Response Management
expert response preparation for Additional Information (AI) requests and deficiency letters
Post-Clearance Support
FDA establishment registration, device listing (Form 3881), and 510(k) summary publication
FDA 510(k) Submission — Frequently Asked Questions
A: Total timelines typically range from 6–14 months depending on whether a Q-Submission is included, the complexity of performance testing, and whether FDA issues an Additional Information (AI) request. The FDA’s Substantive Review target for a Standard 510(k) is 90 days from Acceptance (filing). RABT Global’s Q-Sub strategy reduces the risk of AI requests that extend this timeline.
A: Clinical data is not routinely required for most 510(k) submissions — substantial equivalence is typically demonstrated through bench testing (performance, biocompatibility, electrical safety, software). However, some device types with Special Controls, or devices where bench testing cannot fully characterise performance, may require clinical data. RABT Global advises on this during the regulatory strategy phase.
A: A Q-Submission (formerly Pre-Sub) is a formal mechanism for seeking FDA feedback on your submission strategy before you file. It is strongly recommended for novel device types, complex substantial equivalence arguments, or any case where FDA expectations are uncertain. RABT Global manages Q-Submissions as a standard part of our 510(k) consulting process.
A: eSTAR (Electronic Submission Template and Resource) is FDA’s structured electronic submission format for 510(k) submissions. Since October 2023, eSTAR has been mandatory for most 510(k) submissions. RABT Global’s regulatory publishing team manages all eSTAR preparation and submission.
A: Yes. RABT Global’s FDA deficiency response management service provides expert analysis of FDA Additional Information (AI) requests and prepares comprehensive, strategically sound responses designed to resolve FDA’s concerns fully and move your submission back onto the clearance track.
A: After clearance, you must: register your device establishment with FDA (if not already registered), list your device with FDA (Form 3881), comply with FDA’s Quality System Regulation (21 CFR 820 / QSR), and maintain your 510(k) summary or statement on FDA’s website. RABT Global supports all post-clearance regulatory activities.
A: Yes. If your device requires PMA or is better suited to a De Novo pathway, RABT Global has dedicated services for both — with specialist teams experienced in Class III device submissions and novel device regulatory strategy.
510(k) Submission Checklist
Contents: Step-by-step 510(k) dossier checklist | Common deficiency prevention guide | Predicate strategy worksheet | Testing protocol review checklist | eSTAR section reference guide